Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. MYLAN LABORATORIES LTD. (D.N.J. 2021)
✉ Email this page to a colleague
BAUSCH HEALTH IRELAND LIMITED v. MYLAN LABORATORIES LTD. (D.N.J. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-04-28 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Stanley R. Chesler |
| Jury Demand | Referred To | ||
| Patents | 10,011,637; 7,041,786; 7,799,897; 8,637,451; 9,610,321; 9,616,097; 9,919,024; 9,925,231 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BAUSCH HEALTH IRELAND LIMITED v. MYLAN LABORATORIES LTD.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for BAUSCH HEALTH IRELAND LIMITED v. MYLAN LABORATORIES LTD. (D.N.J. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-03-07 | 55 | Opinion | the ‘024 patent”), 9,925,231 (“the ‘231 patent”) and 10,011,637 (“the ‘637 patent”).) As part…United States Patents Nos. 7,041,786 (“the ‘786 patent”), 7,799,897 (“the ‘897 patent”), 8,637,451 (… (“the ‘451 patent”), 9,610,321 (“the ‘321 patent”), 9,616,097 (“the ‘097 patent”), 9,919,024 (“the …approval to market a drug while that drug is on-patent is patent infringement. 35 U.S.C. § 271(e)(2); see…infringing upon the original drug’s patent by waiting out the patent’s term. If so, the applicant includes | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
